Skip to Main Content

Paper Details

Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer.
Clin Cancer Res
54
2018
517, DNA, DNA copy number, DNA exome, ER, HER2, HER2-Positive Breast Cancer, HER2-enriched subtype, HER2-positive breast cancer, HER2E, Luminal, RNA, TP53, TP53 mutation, Trastuzumab, chromosome 6p, gene expression signatures, gene signatures, immune cells, lapatinib, mRNA, pCR, paclitaxel, stage II to III, trastuzumab, tumor, tumors
Author NameAffiliation
Miki TaniokaLineberger Comprehensive Cancer Center, University of North Carolina
Cheng FanLineberger Comprehensive Cancer Center, University of North Carolina
Joel S ParkerLineberger Comprehensive Cancer Center, University of North Carolina
Joel S ParkerUniversity of North Carolina
Joel S ParkerLineberger Comprehensive Cancer Center, University of North Carolina
Joel S ParkerUniversity of North Carolina
Katherine A HoadleyLineberger Comprehensive Cancer Center, University of North Carolina
Katherine A HoadleyUniversity of North Carolina
Katherine A HoadleyLineberger Comprehensive Cancer Center, University of North Carolina
Katherine A HoadleyUniversity of North Carolina
Terry HyslopDuke University
Matthew G SolowayLineberger Comprehensive Cancer Center, University of North Carolina
Sara M TolaneyDana Farber Cancer Institute
Ian E KropDana Farber Cancer Institute
Donald A Berry
Elaine R MardisThe Research Institute at Nationwide Children's Hospital
Elaine R MardisThe Research Institute at Nationwide Children's Hospital
Eric P WinerDana Farber Cancer Institute
Clifford A HudisMemorial Sloan Kettering Cancer Center
Lisa A CareyLineberger Comprehensive Cancer Center, University of North Carolina
Charles M PerouLineberger Comprehensive Cancer Center, University of North Carolina
Charles M PerouUniversity of North Carolina
  • 1 - 22

Datasets

Release 1.2